New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
07:33 EDTARWRArrowhead receives approval to begin ARC-520 Phase 2a trial
Arrowhead Research announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520. The Hong Kong Department of Health issued a Certificate for clinical trial, allowing the company to proceed with its planned single-dose study of ARC-520 in two cohorts at two dose levels. A site initiation was completed and patient screening will initiate shortly. The company expects top line study results to be available in 3Q14. The Phase 2a study is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study to determine the depth and duration of hepatitis B surface antigen reduction after a single intravenous dose of ARC-520 in combination with entecavir in patients with chronic HBV infection. This study will be conducted in adult male and female patients aged 16 to 65 years, with immune active chronic HBV infection, HBV e antigen negativity, and ongoing entecavir therapy. The primary objective of the study is to evaluate the depth and duration of HBsAg decline in response to a single dose of ARC-520 in combination with entecavir. Secondary objectives include evaluation of safety and tolerability and pharmacokinetic measures.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
09:57 EDTARWRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:06 EDTARWRArrowhead pullback since ARC-520 data an overreaction, says Piper Jaffray
Subscribe for More Information
October 14, 2014
14:54 EDTARWRQVT Financial raises passive stake in Arrowhead to 7.62% from 5.29%
Subscribe for More Information
October 13, 2014
07:12 EDTARWROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 10, 2014
12:11 EDTARWROptions with increasing implied volatility
Subscribe for More Information
October 9, 2014
11:00 EDTARWROptions with increasing implied volatility
Options with increasing implied volatility: ARWR PBR EXXI PWE GST GLNG WTW AFSI ETE VALE
10:00 EDTARWROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:38 EDTARWRArrowhead price target lowered to $12 from $24 at Piper Jaffray
Subscribe for More Information
08:33 EDTARWRArrowhead issues letter to shareholders regarding ARC-520
Subscribe for More Information
06:18 EDTARWRArrowhead downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Arrowhead to Sector Perform citing low-end efficacy in the AASLD abstract. Price target lowered to $9.
05:50 EDTARWRStocks with implied volatility movement; ARWR TKMR
Stocks with implied volatility movement; Arrowhead (ARWR) 158, Tekmira (TKMR) 130 according to iVolatility.
October 8, 2014
16:26 EDTARWROn The Fly: Closing Wrap
Subscribe for More Information
13:12 EDTARWRArrowhead risk/reward favorable, says Deutsche Bank
Subscribe for More Information
11:48 EDTARWRArrowhead sell-off overdone, long-term view unchanged, says Jefferies
Subscribe for More Information
11:10 EDTARWROptions with increasing implied volatility
Subscribe for More Information
10:55 EDTARWRArrowhead ARC-520 treatment effect much lower than expected, TheStreet says
Subscribe for More Information
10:46 EDTARWRArrowhead plunges after HepB data abstract posted
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use